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The Pharmacology of Beta-Adrenergic Blocking Agents 
By BENEDICT R. LUCCHESI AND LEIGHTON S. WWIWTI 
A. DEVELOPMENT OF THE CONCEPT OF ADRENERCK HECXITORS 
T HE endogenously released neurotransmitter substance, norepinephrine, or an injected sympathomimetic amine, ultimately exerts its actions on an 
organ system by combining with an area of the effector cell termed the adre- 
nergic “receptor site.” That drugs and neural chemical mediators react with 
specific receptors in living tissues was suggested by Langley”” in 1905, who 
suggested that effector cells contain both excitatory (motor) and inhibitory 
“receptor substances.” The response of a tissule to epinephrine was dependent 
upon the relative proportions of excitatory and inhibitory receptors present. 
This hypothesis received support in 1906 from the studies of Dale’” on the 
adrenergic blocking activity of the ergot alkaloids, in which it was demon- 
strated that the excitatory actions of epinephrine, with the exception of its 
cardiostimulatory actions, were antagonized or even reversed by ergot. How- 
ever, ergot was without effect on the inhibitory actions of epinephrine. It 
remained for Ahlquist” in 1948 to define clearly the dual adrenergic receptor 
hypothesis. Ahlquist’s concept was based on the premise that two types of 
adrenergic receptors could be demonstrated by differing rank orders of 
potency within a single series of closely related agonists on a variety of 
different adrenergically controlled functions. A total of six sympathomimetic 
amines were studied for their ability to produce vasoconstriction, uterine muscle 
stimulation, contraction of the nictitating membrane, pupillary dilatation, and 
inhibition of gastrointestinal smooth musclc~. A consistent order of potency 
emerged among the six sympathomimetic amines, in which norepinephrine 
was the most potent and isoproterenol the least potent of the amines studied. 
This order of potency was found to be reversed when the same agonists were 
tested for their ability to produce vasodilatation, inhibition of the uterus, and 
cardiac stimulation. On the basis of these results, Ahlquist’ postulated the 
existence of two distinct types of adrenergic receptors, in agreement with the 
earlier observations of Dale”” and proposed the terms SaZ$~a and beta adre- 
nergic receptors only because “excitatory” and “inhibitory” did not describe 
them properly. “Alpha” was applied to those adrenergic receptors most re- 
sponsive to norepinephrine and least responsive to isoprotercnol ( Isuprel ), 
and “beta” was applied to those receptors most responsive to isoproterenol and 
least responsive to norepinephrinr. 
The classification of receptors in different organs is summarized in Table 1. 
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Table L-Classification of Adrknergic Receptors in Selected Organ Systems 
Organ Responses Receptor type 
Heart 
Blood vessels 
increased rate ( automaticity ) 
increased force 
increased rate A-V conduction 
coronary artery constriction 
coronary artery dilatation 
















hronchiolar dilatation heta 
glycogenolysis alpha;beta” 
potassium releasc~ alpha 
lipolysis beta 
“Species varktion exists. The hepatic receptor mediating glycogenolysis in man has not 
heen defined. 
Although the list is incomplete it will serve as a basis for a subsequent dis- 
cussion of beta-adrenergic receptor blocking agents. 
With reference to Table 1 it should be pointed out that according to current 
concepts there are no vascular beta-adrenergic receptors that are inner- 
vated directly (except perhaps in the coronary arteries) and that the veno- 
contrictor and vasoconstricter responses to adrenergic nerve stimulation are 
mediated by alpha-adrenergic receptors. On the other hand arteriolar dilatation 
as a result of beta-adrenergic receptor activation may be elicited by circulat- 
ing catecholamines, since there is no evidence to date to indicate a nerve 
mediated beta-adrenergic vasodilatation. This is in marked contrast to the 
situation which exists in the heart, where the ndrenergically mediated re- 
sponses (sympathetic nerve stimulation) of increased heart rate and contractile 
force are due to activation of beta-adrenergic receptors; the latter respond also 
in a similar manner to circulating catecholamines. 
B. DEYELOPMENT OF BETA-ADRENERGIC RECEPTOR BLOCKIKG AGES-TS 
The classical alpha-adrenergic receptor blocking drugs such as phenoxyben- 
zamine (Dibenzyline) and phentolamine (Regitine) prevent only the re- 
sponses mediated by alpha-adrenergic receptors. \Vhen Ahlquist proposed his 
dual receptor hypothesis, the a&ulable adrenergic receptor blocking agents 
were capable of blocking only alpha-adrenergic receptors. Of necessity, the 
Ahlquist method of characterizing adrenergic receptors, based upon rank 
order of agonist potency, was merely suggestive and received little attention 
until the discovery of dichloroisoproterenol (DCI) by Powell and SlaterS” in 
1958. DC1 was shown to antagonize the inhibitory effects, i.e., beta-adrenergic 
receptor mediated responses, of sympathomimetic amines on the tracheo- 
bronchial system, blood vessels, uterus, and intestine, hut blocked neither 
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Fig. l-Structural formulas of several agents reported to possess beta-adrenergic 
receptor blocking activity. The presence of an asymmetric carbon atom (asterisk) 
in the alky1 side chain of each compound gives rise to dextfo- and ho-rotatory 
optical isomers of which only the Zero-isomer possesses beta-receptor blocking activity. 
the vasopressor (effect of sympathomimetic amines nor the adrenergically- 
induced contraction of the nictitating membrane. In addition DC1 depressed 
the rate and force of contraction of the frog heart and decreased the positive 
inotropic and chronotropic effects of epinephrine. In the same year (1958) 
Moran and Perki&” confirmed the blockade of adrenergic vasodilatation by 
DC1 reported previously by Powell and Slater.&” In addition they demon- 
strated that DC1 produced a highly specific cardiac adrenergic receptor block- 
ade in the dog heart and in the isoIated perfused rabbit heart; i.e., DC1 
specifically inhibited the positive inotropic and chronotropic responses to 
adrenergic nerve stimulation and the exogenously administered catecholamines. 
The specificity of the blockade was demonstrated by the inability of DC1 to 
prevent the augmentation of cardiac contractile force produced by calcium 
chloride, ouabain or theophylline at a time when adrenergic stimuli were 
antagonized. The study by Moran and PerkinsT4 represented the first descrip- 
tion of specific adrenergic blockade of the mammalian heart and supported 
Ahlquist’s hypothesis that the cardiac inotropic and chronotropic adrenergic 
receptors are of the beta type; receptors which subserve inhibitory functions 
in other organs, in contrast to the alpha receptors which subserve sympathetic 
excitatory responses in all organs except the heart. 
Since the introduction of DCI, numerous analogs of isoproterenol, as well 
as many compounds of differing chemical structure have been described as 
possessing beta-adrenergic receptor blocking activity. The interested reader 
should refer to the publications by Biel and Lum’ and by Ariens’ for a dis- 
PHAR1lAcoI.oCU 01' BETA-ADHESENGIC Bl.OcKIS(: \(:I373 313 
cussion of the structure activity relationships and pharmacology of the many 
members belonging to this new class of pharmacological agents. 
The clinical use of DC1 reported by Riddell et al.“* was limited because the 
drug, as shown by Moran and Perkins’” possessed intrinsic sympathomimetic 
activity. Thus, small intravenous doses of 0.25 to 2 mg./Kg. administered to 
the anesthetized dog resulted in tachycardia, a positive inotropic effect, and 
a slight hypotensive action; events which are qualitatively similar to those of 
isoproterenol. 
In 1962, pronethalol ( l- [ 2-naphthyl] -2 isopropylaminoethanol hydrochloride; 
hlderlin, Nethalide), another isoproterenol analog with beta-receptor blocking 
activity, was introduced by Black and Stephenson.ll Pronethalol resembles 
DC1 in its actions except that it possesses considerably less intrinsic sympatho- 
mimetic activity, and shows myocardial depressant activity only in concentra- 
tions approximately 10 times those required to produce beta-receptor blockade. 
Dornhorst and Robinson,“o Stock and Dalello and Pilkington et al.“” reported 
on the clinical pharmacology of pronethalol, making it the first clinically useful 
beta-adrenergic receptor blocking agent. However, the report by Paget”l indi- 
cating that pronethalol was capable of producing lymphosarcomas in mice led 
to its withdrawal from clinical use; with the almost simultaneous introduction 
of propranolol ( 1-isopropylamino-S-[ 1-naphthyloxy ] -2-propanol hydrochloride; 
Inderal) . Black and co-workers9 demonstrated propranolol to possess almost 
no intrinsic sympathomimetic activity and to be approximately ten times as 
potent as pronethalol with respect to beta-adrenergic receptor blocking activity. 
In addition, Tucker et alllo reported that propranolol did not possess carci- 
nogenic potential. In 1965, Black et allo published a detailed comparison of 
the pharmacological properties of pronethalol and propranolol. At about the 
same time that propranolol was introduced, Larson and Lish56 described a new 
group of beta-adrenergic blocking agents; the most outstanding member of the 
series being MJ1999, which was shown to be six times as potent as DC1 as a 
beta-adrenergic blocking agent. Other compounds have been described as well, 
including analogs of methoxamine,l” INPEA, lo3 Ko 592,3? and a sleries of beta- 
receptor blocking agents described by Corrodi et al.n_3 More recently several 
new beta-adrenergic receptor blocking agents have been introduced: H 56/28 
(Aptin) which has been the subject of a comprehensive review,l and ICI 
50172, an agent which has been reported to be highly selective with respect 
to producing blockade of cardiac beta-adrenergic receptors.:‘” 
C. METABOLIC EFFECTS OF ADREMERGIC STIMULATION AND THE CONSEQUENCES 
OF BETA-ADRENERGIC RECEPTOR BLOCKADX 
The administration of catecholamines to animals and man results in a variety 
of metabolic effects which include hepatic release of potassium ion; hepatic, 
cardiac and skeletal muscle glycogenolysis; elevation of blood lactic acid; and 
lipolysis of triglycerides in adipose tissue. 
The catecholamine-induced hyperkalemia is thought to be mediated via 
alpha-adrenergic receptor stimulation. It may be produced by epinephrine, 
norepinephrine but not by isoproterenol and may be prevented by previous 
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Fig. O-Schematic representation of possible pathways of action of catecholamines 
upon carbohydrate and lipid metabolism and possible sites of action of beta-adre- 
nergic receptor blocking drugs and the methylxanthines. 
The work of Sutherland11’ has demonstrated that glycogenolysis is depend- 
ent upon the conversion of the Ienzyme phosphorylase b to its active form, 
phosphorylase a, and that epinephrine resulted in activation of the enzyme. 
Subsequent studies91,9z established that the activation of phosphorylase in 
liver, skeletal and cardiac muscle was mediated via the action of cyclic 3’5’ 
adenosine monophosphate (cyclic 3’5’ AMP), and that the catecholamines 
are capable of increasing the rate of production of cyclic 3’5’ AhlP in prepara- 
tions from liver, skeletal muscle, cardiac muscle, adipose tissue, and probably 
in other tissues as we11.11”.l14 The level of cyclic 3’5s AMP within the cells 
depends upon the relative activities of at least two enzymes, ui~, adenyl cyclase, 
which catalyzes the conversion of adenosine triphosphate ( ATP) to cyclic 3’5’ 
AMP, and a phosphodiesterase which catalyzes the breakdown of cyclic 3’5’ 
AMP to the adenosine monophosphate (5’ AMP). 
In addition to the alterations in carbohydrate metabolism. considerable evi- 
dence exists with respect to the ability of catecholamines to elevate plasma free 
fatty acids by increasing lipolysis of triglycerides in adipose tissue.“‘; Similar 
to the events which lead to glycogenolysis. cyclic 3’5” AMP appears to play a 
prominant role in mediating the lipolytic action of the catecholannnes.lS~“’ 
Studies by Klainer et a1.j’ and Rutcher’7 have shown that catecholamines 
increase adenyl cyclase activity as well as the levels of cyclic 3-Y AMP in 
adipose tissue. The scheme presented in Fig. 3 summarizes the metabolic 
sequence of events following adrenergic stimulation. 
It is not possible, at present, to classify the adrenergic receptors which 
mediate the hepatic glycogenolytic effects of the catecholamines as alpha or 
beta on the basis of available evidence. Part of the difficulty arises from the 
observation that the relative potencies of various catecholamines in inducing 
hyperglycemia are quite different from their potencies in activating beta- 
receptors of other tissues; and antagonism of the metabolic responses has not 
correlated well with either alpha or beta-blockade. Furthermore, the results 
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are complicated by the existence of marked species differences. Thus, Mayer 
et aLG6 reported a prevention of the catecholamine-induced hyperglycemic 
response in the dog by prior administration of a beta-receptor blocking agent. 
This is in contrast to alpha-adrenergic blocking agents which others have re- 
ported to be ineffective.4’j,c” Furthermore, the studies by Murad et al.” have 
shown that the accumulation of cyclic 39 AhlP following the addition of 
epinephrine in dog liver homogenates could be prevented by the beta-receptor 
blocking agent, DCI. 
The results obtained in humans with respect to the blockade of catecholn- 
mine-induced hyperglycemia are in marked contrast to studies performed in 
the dog. Pilkington et al.,” Muir et al.,;” and Hunninghake et al.*” have reported 
that beta-adrenergic receptor blockade failed to prevent or reduce the hyper- 
glycemia associated with exogenous catecholamine administration or that 
associated with exercise. An uneqlained observation is that reported by 
Hunninghake et al.‘” in which butoxamine administration resulted in a lowering 
of fasting plasma glucose levels in man, but did not prevent the catechola- 
mine-induced hyperglycemia in man.” The inability to classify the hepatic 
glycogenolytic adrenergic receptor in man is further emphasized by the find- 
ing that isoproterenol, a specific beta-adrenergic receptor agonist, does not 
produce a hyperglycemia in IIXU~~” in contrast to its action in the dog.;‘& This 
observation agrees with those of Murad et al.‘: with respect to the relativt 
potrncies of the catecholamines in cle\&ng the levels of cyclic 3’5’ .-ZMP in 
dog liver homogenate preparations and pr~~vcntion of the IW~OIISV 1)~ tlx, 
betn-blocking agent DCI. The a\&~ble evidence suggests that catechc,lnminr- 
induced hyperglycemia in the clog, but not in man, involves interaction \rith 
rccqtors which are, or rescrnble, beta-aclrenrrgic receptors. 
The stimulation of cyclic 3’5’ AhJP, the activation of phosphorylase and 
glyc:ogenolysis in dog and rat heart preparations are antagonized by beta- 
adrcnergic receptor blockade. 1i.5 ‘.CG.77 Thus, glycogenolysis in m)ocardial tis- 
sue is classified as a beta-receptor mediated (‘1 ent. 
The role of the sympathetic nervous system in fat deposition and mobiliza- 
tion’ 2 I as well as the ability of injected epinephrine to mobilize lipids”‘~‘“” 
Iin\ c been adequately demonstrated. Epinephrinc and norepinephrine elevate 
plas~na free fatty acids in man and dog:“.“; and promote lipolysis in adipose 
tissue in vitro.“” Isoprotercnol, likewise, has been demonstrated to induce free 
fatty acid release in man.” Finally, stimulation, with frccluencics within the 
physiologic range, of sympathetic nerves iniier\ating canine subcutaneous adi- 
post tissue, promotes the release of free-fat@ acids.‘“’ 
The free-fatty acid mobilization following adrencrgic stimulation is sus- 
ceptible to blockade by various adrencrgic blocking agents. Results obtained 
with alpha-receptor blocking agents are not in full agreement. Ergotamine, 
Dil)enaminc, phenoxybenznmine and phcntolamine ha\-e been reported to 
produce effective blockade of lipid mobilization in rat, dog, and 111a1l~:‘.~““(“.“‘” 
whereas others have not observed similar results with these blocking agents.<’ 
Fain et aI.“’ have reported that phcnosybenz~lmine had little inhibitory effect 
on the lipolytic action of catecholamines in fat celIs but reduced that of growth 
hormone and glucocorticoid: ; It has been r(sported that both phenox~benza- 
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mineloo and butoxaminelOu reduce fatty acid mobilization in diabetes, and 
their effects are taken as proof of the involvement of the adrenergic nervous 
system in diabetic ketosis. However, these effects could probably have been 
due to the antagonism of the lipolytic effect of growth hormone and gluco- 
corticoid.36 
The beta-adrenergic blocking agent, DCI, has been shown to block the 
effect of catecholamines in fatty acid mobilization in dogs66 and to prevent 
catecholamine-induced lipolysis in incubated adipose tissue.58 Propranolol, 
likewise, has been shown to block the lipolytic action of epinephrine,“” but 
did not block the lipolytic activity of growth hormone and dexamethasone”’ 
or that of ACTH.“F Similar results have been reported by Stock and Wester- 
mann’ll using the beta-receptor blocking agent Ko 592. 
There are at least three different mechanisms for activation of lipolysis in 
fat cells: the interaction of catecholamines with a beta-adrenergic receptor 
which results in a rapid activation of a triglyceride lipase (uin cyclic 35’ 
AMP). ACTH may produce a similar effect, but does not react with the 
catecholamine receptor site. The stimulation of lipolysis by growth hornlone 
and a glucocorticoid appears to be mediated through a mechanism which 
involves RNA and protein synthesis and thus ‘exhibits a lag phase of several 
hours.s” It is perhaps the interplay of all the above mentioned factors which 
permits the homeostatic control of lipid mobilization. Thus, more than one 
site of drug-induced blockade can conceivably exist. Comparison of the effects 
of various drugs indicates that some drugs which have been described as 
adrencrgic antagonists are actually nonspecific inhibitors of lipolysis. Thus, 
alpha blocking drugs preferentially block the lipolytic action of growth hor- 
mone and glucocorticoids. Phentolamine will block the lipolytic action of 
epinephrine, but proporanolol, a beta-blocking drug, is 300 times more ef- 
fective as well as being a specific competitive antagonist of catecholamine- 
induced Iipolysis, with little effect on the lipolysis induced by other agents.‘“’ 
I?ain3” has suggested that the receptor for catecholamines in isolated fat cells 
should be classified as a beta-adrenergic receptor on the basis of the high 
specificity and potency of beta-adrenergic blocking drugs as antagonists of 
catecholamine-induced lipolysis and secondly, the order of potency of the 
lipolytic effects of catecholamines, e.g., isoproterenol>epinephrine and no- 
repinephrine. 
D. EFFECTS OF BETA-ADRESERGIC RECEPTOR BLOCKADE UPON THE 
CARDIOVMCULAR SYSTEM 
1. Hemod,ynumics 
The blockade of cardiac beta-adrenergic receptors, as first demonstrated by 
Moran and Perkins?* with DCI, prevents or reduces the usual positive inotropic 
and chronotropic actions resulting from either catecholamine administration 
or cardiac sympathetic nerve stimulation. The depressor response to isopro- 
terenol was likewise reduced or abolished, while the pressor responses to 
epinephrine and norepinephrine were unaffected or potentiated. Subsequently, 
Black and Stephensonl’ reported similar effects with pronethalol. Unfortu- 
nately, both DC1 and pronethalol possessed significant intrinsic sympatho- 
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mimetic actions2g~7” in the anesthetized dog, making it diihcult to assess the 
true significance of myocardial beta-receptor blockade. The introduction of 
propranolol’ provided the first beta-receptor antagonist devoid of intrinsic 
sympathomimetic activity. In anesthetized dogs with intact cardiac innerva- 
tion and intrinsic sympathetic tone, propranolol has been reported to decrease 
the resting heart rate, myocardial contractile force and blood pressure, after 
doses which produce beta-receptor blockade.‘” The effects of given doses of 
isoproterenol ( 0.004 to 312.$g./Kg. ) on systemic arterial pressure and myo- 
cardial contractile force were reduced or completely blocked by progressively 
increasing doses of propranolol; the larger doses of isoproterenol being able 
to surmount the blocking effect of propranolol on myocardial contractile 
force.78 Flacke et a1.38 have reported that propranolol, in doses up to 1 mg./Kg., 
did not exert a negative inotropic or negative chronotropic effect in anesthe- 
tized dogs in which autonomic tone had been eliminated by sympathetic and 
parasympathetic blockade. Arterial pressure, aortic blood flow and atria1 pres- 
sures were unaltered.38 However, a dose of 3 mg./Kg. of propranolol did 
cause a decrease in heart rate, contractile force and blood pressure, and in- 
creased left atria1 pressure. Flacke et a1.3s concluded that in the absence of 
endogenous neurogenic tone, propranolol has no direct depressant effect upon 
cardiovascular function in doses which cause beta-receptor blockade. 
The effect of beta-adrenergic receptor blockade (propranolol; Kii 592) on 
the racing performance of normal greyhounds and greyhounds with chronic 
extrinsic cardiac denervation was reported by Donald et al.” Beta-receptor 
blockade resulted in a slight increase in racing time in the nomlal animal with 
only a slight reduction in the maximal heart rate. In the animals with chron- 
ically denervated hearts, racing time was prolonged, cardiac acceleration was 
severely limited, and the animals finished running in a state of collapse. Thus. 
maximal performance is dependent upon the cardiostimulant action of both 
sympathetic nerves and circulating catecholamines. Analogous studies in man:” 
were carried out to assess the effects of beta-adrenergic blockade on the 
circulating responses to treadmill exercise in normal subjects and subjects 
with heart disease. In normal subjects propranolol produced a fall in the 
endurance time to maximal exercise, which was 40 per cent less on the average 
than the control. This was associated with decreases in cardiac output (22 per 
cent), mean arterial pressure ( 15 per cent ) . left ventricular minute work 
(3-1 per cent), and maximal oxygen uptake (6 per cent). Increases in the 
arteriovenous oxygen difference (12 per cent) and the central venous pressure 
(2.8 mm. Hg) were noted after beta-receptor blockade. Similar results were 
obtained in patients with heart disease who were made to exercise maximally. 
Under conditions of sub-maximal exercise, propranolol produced similar cir- 
culatory responses with the exception that oxygen uptake was not altered. 
The decrease in cardiac output (18 per cent below control) was compensated 
for by an increase in the arteriovenous oxygen difference. 
The response of heart size to exercise measured before and after beta- 
receptor blockade has shown an increase in ventricular end-diastolic dimen- 
sions, whereas exercise in the unblocked, normal subject results in a decrease 
in ventricular dimensions.‘“JUG Recent studies by Robin et aL9” have demon- 
strated the effects of propranolol upon the hemodynamic parameters in pa- 
tients with and without coronary artery disease. Intravenous propranolol pro- 
duced a fall in velocity of shortening of myocardial fibers, heart rate, dp/dt, 
stroke index and left ventricular minute work. However, there was a concom- 
tunt increase in left ventricuIar end-diastolic pressure which was greater in 
patients with arteriosclerotic heart disease. In both groups, propmnolol re- 
sulted in a decrease in mean systolic ejection rate and in left ventricular 
minute work. Sowton and Hamer’” likewise demonstrated that heta-adrener- 
gic receptor blockade prolonged the systolic ejection period at rest and during 
exercise and increased ventricular dimensions during exercise.Lg.“‘~’ Both al- 
terations tend to increase myocardial oxygen consumption by prolonging the 
time during which the ventricle maintains tension and by increasing the 
ventricular wall tension necessary to maintain a given pressure. However, the 
decrease in the velocity of fiber shortening and the extent of fiber shortening 
produced by beta-adrenergic blockade”‘,~“~’ coupled with the negative chrono- 
tropic response and a reduction in arterial pressure”“.‘” should reduce myo- 
cnrdial oxygen demands, Sonnenblick et al.“” using the maximum and IIKZU~ 
rates of ventricular ejection and the rate of left ventricular pressure rise 
( Wdt ) as determinants of myocardial fiber shortening, demonstrated a direct 
correlation between myocardial oxygen consumption and velocity of contrac- 
tion. Thus, following propranolol the increased myocardial oxygen demand is 
offset by those factors which tend to reduce myocardial oxygen consumption. 
The net effect is a balance between these diverse effects in which myocardial 
osygen consumption may increase or decrease. A number of studies”~“‘~“” 
have demonstrated a reduction in myocardial osygen consumption following 
beta-adrenergic receptor blockade. In a recent clinical study, Lewis and 
Brink”; have evaluated the hemodynumic and cardiac metabolic effects of 
propranolol in patients with ischemic heart disease. The results of this study 
indicated that 10 mg. of propranolol intravcno’usly produced a significant re- 
duction in heart rate, left ventricular isometric tension development (dp/dt), 
whereas left ventricular end-diastolic pressure rose; findings which have been 
stressed in previous clinical and physiologic studies.‘!“.“7~‘2’; Myocardial oxygen 
consumption decreased in 4 patients after propranolol, but an increase was 
noted in 3 additional patients-results which might possibly have been at- 
tributed to the net balance between the olpposing factors which determine 
whether myocardial oxygen consumption is reduced or increased.:“’ 
The hemodynamic alterations of the coronary vascular bed resulting from 
catecholamines and the role of adrenergic receptors in the regulation of myo- 
cardial blood flow have been of interest, Some studies have indicated that 
epinephrine or norepinephrine are solely coronary \‘asodilators,“.‘:‘” while 
others3 have suggested that their primary action is one of vasoconstriction and 
that the increased coronary flow usually observed is secondary to metabolic 
changes associated with myocardial stimulation. Isolated smooth muscle 
preparations from coronary arteries have been shown to possess both alpha 
and beta receptor activity, with a clear difference between the ratio of alpha 
to beta receptors in small coronary arteries and that in large coronary ar- 
teries.12.1:“’ Strips from small coronary arteries of humans, rabbits, dog, and 
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monkeys show predominantly or exclusively beta-adrenergic activity, whereas 
responses of large coronary arteries differ in that alpha receptor activity 
associated with smooth muscle contraction predominates. The responses couId 
be preventied by appropriate receptor blocking agents. Folle and Aviado3” 
showed in anesthetized dogs that a beta-receptor blocking agent abolished 
the coronary vasodilatation produced in response to systemic anoxemia. Klocke 
and associates”” observed coronary vasodilatation after the intracoronary in- 
jection of isoproterenol; a response which could be prevented by prior beta- 
adrenergic receptor blockade. Parratt and Grayson”” have suggested that the 
alpha-receptor mediated vasoconstriction following blockade of beta-adrcner- 
gic receptors leads to an increase in coronary vascular resistance and a de- 
crease in coronary blood flow. The results of other studies”’ suggest that the 
increase in coronary vascular resistance which occurs following propranolol is 
not related entirely to specific beta-adrenergic receptor blockade. The major 
part of the increased resistance appears to be associated with the reduced 
myocardial energy requirements resulting from cardiac slowing and reduction 
in the rate of tension development. 
2. Pharmacologic Basis for the Cise of Betu-Adrenergic Receptor Blocking 
Agents in the Management of Idiopathic Ziypertrophic Subaortic Stenosi.v 
otzd Tetrulogy of Fallot 
Drugs which exert a positive inotropic effect-e.g. digitalis, isoproterenol- 
are known to increase the systolic pressure gradient across the outflow tract o’f 
the left ventricle, and decrease the effective size of the outflow orifice in pa- 
tiwts with IHSS.13,‘* Similar effects occur with exercise or emotional excitn- 
tion. In addition, exercise-induced angina pectoris is a distressing symptom in 
many patients with IHSS due to the increase in myocardial oxygen consump- 
tion. During exercise, the enhanced adrencrgic drive increases left \,entriculnr 
work by increasing its output and by increasing obstruction to outflow.” 
Studies of tissue resected at operation from the outflow tract of the left \YW- 
triclr of patients with obstructive curdiom!opathies have demonstratt~d pro- 
liferation of sympathetic nerve fibers in the abnormal muscle as well as an 
increased content of norepinephrine.“* This lends further significance to the 
role of the sympathetic nervous system in the physiologic derangements in 
patients with IHSS. Thus, in ZHSS beta-adrenergic receptor blocking agents 
a-ouId appear to be useful in modifying or preventing the pathophysiologic 
effects of augmented sympathetic nerve discharge. Studies by Goodwin et al.’ I 
and Harrison et aL4” showed that pronethalol had little effect upon gradients 
across the left ventricular outflow tract in patients at rest. However, gradients 
enhanced by exercise or by isoproterenol infusions were reduced by prone- 
thalol along with a return toward normal of left ventricular dp/dt.4& Suh- 
sequent studies with propranolol have shown that 10 of 13 patients with 
IHSS were subjectively improved, effort tolerance improved in 7 of 9 patients, 
and syncope was prevented in 5 of 6 patients.‘O All patients had an ejection 
type of systolic murmur which decreased in 9 of the 13. Intensification of the 
lnurmur after exercise no longer occurred in 7 of 13, all of whom received 5 
to 20 mg. of propranolol orally three times daily.‘” The amelioration of angina 
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pectoris in patients with IHSS following propranolol (80 to 480 mg. daily) 
has been reported by Cohen and Braunwald.zz 
The mechanisms by which propranolol benefits the patients with IHSS may 
be: the bradycardia following beta-adrenergic blockade may increase cardiac 
volume which may relieve obstruction; the reduction in cardiac work may 
prevent angina pectoris; beta-adrenergic blockade prevents the adrenergically 
mediated augmentation of ventricular contraction (dp/dt) associated with 
exercise, thus decreasing obstruction to the left ventricular out%ow tract, and 
decreasing the left ventricular-aortic gradient. 
In Fallot’s tetralogy the magnitude of the right to. left shunt is dependent 
on the relative resistances to blood %ow through the aorta (systemic vascular 
resistance) and the pulmonary artery (narrow muscular right ventricular out- 
flow tract). Augmentation of cardiac contractile force, as with exercise, further 
narrows the right ventricular o&low tract leading to an intensification of the 
cyanosis and possible syncope.1’8 The right to left shunt in patients with Fal- 
lot’s tetralogy may be considerably increased by drugs such as norepine- 
phrine, reproducing the clinical picture of the hypercyanotic spellP; an ob- 
servation which would suggest that the right o&low tract obstruction is 
increased by enhancement of sympathetic nerve activity. That this may be 
the case is supported by the finding that beta-adrenergic receptor blockade 
will reduce the fall in arterial saturation which occurs during exercise in 
patients with the tetralogy.“’ Thus, beta-adrenergic receptor blockade, by 
preventing the augmented ventricular response to sympathetic nerve stimula- 
tion, decreases right ventricular outflow tract obstruction. In addition, the 
increase in peripheral arterial resistance leads to a reduction in the right to 
left shunt and an increase in pulmonary blood %ow.~~ 
Cummings and Car? reported significant improvement in 3 infants having 
hypoxic spells treated with propranolol; these results were confirmed by Shak 
and Kidd.l”” Both exercise and isoproterenol infusion result in a drop in 
arterial oxygen saturation and an increase in the right to left shunt in patients 
with tetralogy; events which could be abo’lished or reduced in magnitude by 
previous intravenous infusion of propranolol in a dose of 0.2 mg./Kg. Pro- 
pranolol, in doses which abolished the response to isoproterenol, produced a 
rise (5-10 per cent) in resting arterial oxygen saturation. Although propranolol 
administered orally (l-4 mg. every 8 hours) was reported to be ineffective,g’ 
there seems little doubt that intravenous propranolol has an important part to 
play in the management of infants with Fallot’s tetralogy whose condition 
deteriorates rapidly because of syncopal attacks, if only to allow a longer 
time in which to prepare them for surgical treatment. 
3. Antiurrhythmic Effects 
a. Catecholamine-induced arrhythmias. As proposed by AlJquist,zJ there 
are hyo types of adrenotropic receptors in the mammalian heart, the beta- 
receptors which subserve the inotropic and chronotropic responses to adre- 
nergic stimuli, and the alpha-receptors which mediate the ectopic excitation 
induced by sympathetic stimuli. Evidence for the function of the alpha-receptor 
in the myocardium was based upon the observation that Dibenamine (an 
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alpha-adrenergic receptor blocking agent) prevents arrhythmias resulting 
from the combined administration of a hydrocarbon anesthetic agent and 
epinephrine. However, this concept was challenged by Moe et al.,‘l who 
demonstrated that the protection provided by Dibenamine against the hydro- 
carbon-epinephrine arrhythmia was due to the ammlment of the vasopressor 
effect of epinephrine by the alpha-receptor blocking agent and that mechanical 
elevation of the blood pressure could restore the arrhythmogenic action of 
epinephrine.‘l Following the introduction of DCI, several investigators com- 
pared the effectiveness of alpha- and beta-receptor blocking agents in antag- 
onizing catecholamine-induced arrhythmias. 41.i2.i3 Infusion of norepinephrine 
during the application of successive stimuli to the right and left ventricles pro- 
duced ventricular arrhythmias ranging from extrasystoles to ventricular fibril- 
lation$l arrhythmias which could be prevented by beta-adrenergic receptor 
blockade with DCI, but not by alpha-receptor blockade. Moore and Swain:” 
and Moran et a1.i3 observed that ventricular fibrillation produced by the com- 
bined use of the substituted propiophenone, U-0882, and catecholamines was 
antagonized by beta-receptor blockade. DC1 also inhibited the epinephrine 
and norepinephrine-induced ventricular arrhythmias in conscious dogs fol- 
lowing coronary artery ligation, but did not abolish the spontaneous ventricu- 
lar arrhythmias 24 hours after myocardial infarctioni Subsequent studies with 
pronethaI and propranolol supported the previous observations in showing 
that catecholamine-induced arrhythmias could be antagonized by specific 
beta-receptor blockade.5g@.63 Studies in the experimental animal have shown 
the beta-adrenergic blocking agents to be ineffective in preventing or terminat- 
ing the spontaneously developing arrhythmias following acute myocardial in- 
farction.5g~73 However, beta-adrenergic receptor blocking drugs are capable of 
preventing catecholamine-induced arrhythmias in animals previously subjected 
to acute myocardial infarction.5”BG3 The dextro-isomers of pronethalol and pro- 
pranolol, which lack beta-receptor blocking properties, were unable to prevent 
catecholamine-induced rhythm disturbances,59,G” therefore demonstrating the 
specificity of the ant&rhythmic effect which is mediated via blockade of 
cardiac beta-adrenergic receptors. To date, all known cardiac beta-adrenergic 
receptor blocking agents are able to produce this specific antiarrhythmic effect 
with the only difference being quantitative in nature. 
11. Atrioventriculm conduction and beta-atlrenergic receptor blockade. It is 
well known that the sympathetic nervous system has an important role in 
ragulating both the frequency of cardiac-impulse generation and the functional 
refractory period of atrioventricular conduction.“3 When normal atrioventricu- 
Iar conduction takes place, the ventricular contraction rate is limited by the 
ntrioventricular nodal system, which has bleen shown in experimental animals 
to have a longer effective refractory period than atria1 or ventricular tissue.:* 
Sympathetic denervation,:;. ‘Is depletion of cardiac norepinephrine stores by 
rtserpine,‘:’ and beta-adrenergic receptor blockade by propranololg”~llg have 
been shown to increase the atrioventricular functional refractory period and to 
slow atrioventricular conduction. The effect of propranolol on ventricular rate 
during supraventricular arrhythmias is not usually associated with an alteration 
in atria1 rate or rhythm. Rather it results primarily from a prolongation of the 
refractory period of the atrioventriculur-conductil7g system which is controlled 
to a large cstent by the activity of the adrenergic nervous system and, as 
demonstrated in the experimental animal, may be markedly prolonged by 
beta-adrenergic receptor blockade.!‘” Furthermore, one may expect the action 
of propranolol upon atrioventricular conduction to be additive to that of 
digitalis,9” and provides a means of further decreasing the ventricular rate. 
c. Digitalis-induced arrl~ytlmiu. As has been discussed previously, the 
capacity to antagonize catecholamine-induced arrhythmias with beta-receptor 
blo’cking drugs is dependent upon specific beta-adrcnergic receptor blockade 
an d is a property possessed by all drugs belonging to the class of beta- 
adrenergic receptor blocking compounds. That beta-adrenergic receptor block- 
ing agents possess antiarrhythmic properties independent of their ability to in- 
duce specific receptor blockade was demonstrated initially with dichloroiso- 
proterenol, which was shown to antagonize digitalis-induced arrhythmias in 
the experimental animal. F1 The non-specific anti-arrhythmic property of the 
beta-adrenergic receptor blocking agents was established more firmly by the 
demonstration that the de&o-rotatory isomers of pronethalol and propranolol, 
which do not produce beta-receptor blockade, were able to antagonize experi- 
mentally-induced digitalis arrhythmias.“‘,“” It is of further importance to note 
that not all beta-adrenergic receptor blocking agents are capable of sup- 
pressing digitalis-induced arrhythmias although they antagonize catechola- 
mine-induced rhythm disturbances,l”Z-““-a finding which emphasizes the non- 
specific antiarrhythmic action of propranolol. Thus, the beta-adrenergic block- 
ing drugs may be classified into two groups based upon the qpe of rhythm 
disturbances which they suppress: those which antagonize catecho~lamine as 
well as digitalis-induced arrhythmias, and those which specifically suppress 
catecholamine-induced arrhythmias. In the former group are such agents as: 
dichloroisoproterenol, pronethalol, propranolol, and H56/38.1,“‘.“‘-‘;:’ The latter 
group consists of INPEA and MJ 1!399.7”~‘~1’~” 
The effects of several beta-adrenergic receptor blocking agents upon myo- 
cardial transmembrane action potentials have been studied in an attempt to 
elucidate the mechanism of their nonspecific antiarrhythmic properties. Initial 
studies by Sekiya and Vaughan Williams”’ revealed that quinidine and 
pronethalol raised the electrical threshold and reduced the conduction velocity 
and the maximum frequency at which atria would follow a stimulus. Both 
quinidine and pronethalol affected intracellular action potentials in the same 
way, causing little change in the resting potential or duration of the action 
potential, but reducing the overshoot potential and slo’wing the rate of rise 
of the action potential. Subsequent studies with propranolol’ls provided similar 
observations with respect to alterations in the transmembrane action potential 
and as with the previous agents suggested a mechanism which involved in- 
hibition of a sodium-ion carrier system. More recently, Davis and Temte’” 
have studied the effects of propranolol on the transmembrane potentials of 
single ventricular muscle fibers and Purkinje fibers and the effect of pro- 
pranolol on the response of Purkinje fibers to epinephrine. Processes involved 
in depolarization as well as those associated with repo’larization were affected. 
Decreases in velocity of depolarization and in magnitude of overshoot and an 
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impairment in ability to respond to rapid stimulation occurred in both fiber 
types studied. Significant changes in the repolarization process were limited 
to Purkinje fibers. Doses of propranolol that greatly accelerate repolarization 
of Purkinje fibers had relatively little effect on this feature of ventricular 
muscle fibers in the same preparation. PropranoIol is not unique among anti- 
arrhythmic agents with respect to its action on shortening the refractory period 
of Purkinje fibers. Diphenylhydantoin has been shown to produce a similar 
effect.’ 
:ls shown by Davis and Temte,“; propranolol prevents local responses and 
decremental conduction-actions which are perhaps more sign&cant in ac- 
counting for its antiarrhythmic action, The results of these studies indicated 
that propranolol produces changes in the transmembrane potential that are in- 
dependent of an action on beta-receptors. Furthemlore, propranolol was shown 
to prevent the increase in diastolic depolarization in Purkinje tissue caused 1~) 
epinephrine; an action which may account for the ability of beta-receptor block- 
ing agents to prevent epinephrine-induced arrhythmias. On the basis of electro- 
physiological studies, it is possible to speculate upon the possible mechanisms 
involved in the “specific” and “nonspecific” antiarrhythmic properties of 
propranolol. 
The most serious side effects of beta-adrencrgic receptor blockade with 
propranolol in the management of digitalis arrhythmias ‘are hypotension, brady- 
card& the aggravation of cardiac failure, and ventricuIar standstiI1. Patients 
with moderately advanced cardiac disease and whose hearts are to a large 
extent dependent upon their adrenergic nervous system for circulatory support 
may experience acute congestive failure upon the administration of a beta- 
ndrenergic receptor blocking agent. This was first noted by Stock and Dale,“” 
n-ho reported the aggravation or precipitation of heart failure following 
pronethalol and advised the cautious use of the drug in the presence of &al)- 
lished or incipient heart failure. Impairmcant of cardiac function may bc 
manifest not only in an inability to augment the cardiac output, but also in a 
diminished ability to escrctc sodium, with resultant fluid accumulation and 
cdema.j4 In patients with normal or only mildly impaired cardiac function, 
the only effect of propranolol will be to lower the cardiac output during 
exercise and to alter the diurnal pattern of sodium excretion. -4s heart failure 
progresses in severity, the effects of withdrawing sympathetic stimulation of 
the myocardium become more impressive and may result in actual sodium 
retention. In a patient with severe heart failure, propranolol will intensif) 
the clinical manifestations of heart failure through mechanisms other than 
sodium retention. Since the destro-isomer of propranolol is devoid of b&a- 
receptor blocking activity, but still possesses antiarrhythmic activity against 
digitalis ;\rrhythmias,“‘~,“” it might serve as a valuable therapeutic agent in 
instances where reduction in cardiac sympathetic tone would be clisad\xn- 
tngeous. 
The depressant effect of propranolol on the atrioventricular node, although 
responsible for many of its useful clinical effects, is also a potential hazard. In 
patients with pre-existing defects of atrioventricular conduction, complete 
heart block may be produced by Betsy-blockade.“; However, it is important 
to note that the myocardium will respond to mechanical or electrical stimuli 
following suppression of all pacemaker activity by propranolol.‘“!’ 
The bradycardia with the resultant decrease in cardiac output and the de- 
velopment of hypotension may be especially hazardous in patients dependent 
on the maintenance of a good heart rate for their cardiac function, particularly 
those with mitral and aortic incompetence. The blockade of beta-adrenergic 
receptors prevents the use of agents such as isoproterenol to augment the 
cardiac output, unless excessive dosages are administered to o\;ercome the 
competitive receptor blockade, which may impose additional hazards upon 
an already critical patient. Recently, the hormone glucagon has been shown 
to be capable of augmenting cardiac contractility and heart rate in the pres- 
ence of beta-adrenergic receptor blockade in the e?rperimental animal”@ and 
has been found to possess positive inotropic and chronotropic actions in man 
unaccompanied by the enhancement of ventricular irritability or increased 
peripheral resistance?’ Similar observations with glucagon have been made 
in patients developing acute congestive failure following the use of propranoIo1 
for the treatment of digitalis-induced arrhythmias.“” In addition, it has been 
observed that glucagon will reverse the depression of atrioventricular nodal 
transmission produced by propranolol in the e‘xperimental animal.lZ3 The 
experimental data and the limited clinical experience with glucagon suggest 
that the hormone may provide hemodynamic benefits in situations resulting 
from beta-adrenergic receptor blockade. 
Although clinical data is lacking at present, beta-adrenergic receptor block- 
ade, as indicated in the experimental animal, may be of value in the preven- 
tion of post-counter shock arrhythmias. The incidence of counter shock 
arrhythmias has been reported to be higher in digitalized than in non- 
digitalized patients. g0 Studies in the experimenta animal have indicated that 
dichloroisoproterenol, pronethalol, and propranolol reduced the duration of 
post-counter shock arrhythmias in both normal dogs and dogs given ouabain,ll” 
an action which is believed to be the result of beta-adrenergic receptor 
blockade. 
4. Antih ypertensive Action 
The use of beta-receptor blocking drugs in hypertensive therapy was re- 
ported by Prichard”’ and subsequently confirmed by Prichard and Gillam 
using propranolol. 88 An appreciable hypotensive action was not seen follow- 
ing acute administration of pronethaIols7 or of propranololqs in patients in 
normal cardiac rhythm, A slight hypotensive effect was observed after 1 to 2 
weeks of oral administrations7 with a more pronounced effect noted after 4 or 
more weeks of oral administration. Dosage of propranolol was commenced at 
10 mg. four times daily, and increased by increments of 10 mg. each dose 
each week, 20 mg. increments being made when higher dose ranges were 
reached. 
The hypotensive effect of beta-receptor blockade appears to result from a 
decrease in cardiac output. Furthermore, beta-receptor blockade would pre- 
vent the cardiac component of various stimuli responsible for transient rises 
in blood pressure. 
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Postural hypotension was not a feature nor was exercise hypotension observed 
in patients receiving oral propranolol. 8g Its mode of action is different from 
most commonly employed antihypertensive agents which act primarily by 
reducing peripheral resistance, and the full hypotensive effect is not usually 
seen for several weeks after the start of therapy. In discussing the possible 
mechanisms for the antihypertensive action of propranolol it is interesting that 
Frolich and Page 4o have suggested that they observed in their patients, “a 
modification of behavior, best described as a tranquilizing effect.” Thus, in 
addition to a hemodynamic component there may be a more central one 
produced by these drugs. A centrally mediated hypotensive action for pro- 
pranolol has been demonstrated in the experimental anima1.7”s 
5. Miscellaneous Studies 
a. Parkinsonian tremor. The beta-receptor blocking agents pronethalol and 
propranolol have been reported to abolish the increase in tremor of patients 
with Parkinson’s disease during infusions of epinephrine.8u In a double blind 
crossover trial involving 18 patients, the oral administration of propranolol 
(30 mg. three times daily for a week) was reported to have produced a 
significant reduction in the tremor. However, Vas,“’ employing intravenous 
propranolol ( 10 mg. ) , was unable to demonstrate a significant reduction in 
recorded tremors. 
11. Vent&tory function and bronchial asthma McNeille8 has reported on 
side effects of beta-receptor blockade in asthmatics. He measured the 1 second 
force expiratory volume (F.E.V.,) before and after intravenous propranolol 
(S-10 mg.) and noted a pronounced fall in 4 of 10 patients. By using sensitive. 
body plethysmographic methods, airway narrowing has also been observed 
in normal subjectsG9 Similar results in asthmatic patients have been reported 
by Deumer” who administered propranolol in the form of an aerosol. Twenty- 
one of 25 patients who inhaled propranolol showed a sudden and pronounced 
fall in ventilatory function. Of interest was the observation that the dextro- 
isomer of propranolol (Dexinderal ) did not alter the FEV, in asthmatic 
patients;GQ an observation which emphasizes the role of the beta-adrenergic 
receptor in the control of airway resistance. The bronchospasm produced by 
propranolol in asthmatics is the result of beta-receptor blockade which leaves 
the parasympathetic system relatively unopposed or may increase the sensi- 
tivity of the bronchial smooth muscle to either endogenous or exogenous stimuli 
as a result of the relative inability of the smooth muscle to respond to endo- 
genous beta-adrenergic stimulation. 
Aminophylline is a suitable bronchodilator when a wheeze or a frank 
attack of asthma develops in a patient receiving propranolol.6g 
These results suggest that beta-adrenergic blocking drugs should be used 
with caution in asthmatics. Furthermore, the deztro-isomers of beta-receptor 
blocking agents may be of value in certain clinical situations involving asth- 
matic patients. 
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